Fundamentals: Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment. Average 1 year target from analysts = 54.
Technical: To allow the stock some fluctuation the stop could be around 40.2 level. Target could be around the previous top - 55-56 area.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.